
Opinion|Videos|May 7, 2025
Addressing Potential Barriers to Implementing Hypercortisolism Screening in Practice
Experts discuss potential barriers to screening for hypercortisolism in primary care and specialty settings, ways to address these barriers, when a patient should be referred to endocrinology after screening, and how primary care clinicians and specialists can collaborate effectively to identify, screen, and refer patients with hypercortisolism to optimize patient care.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are some potential barriers to screening for hypercortisolism in primary and specialty care settings?
- What are some ways to address and overcome these barriers?
- When should a patient be referred to endocrinology after hypercortisolism screening?
- How can primary care clinicians and specialists collaborate effectively to identify, screen, and refer patients with hypercortisolism in a timely manner to optimize patient care?
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

